Becton Dickinson vs Dexcom (BDX vs DXCM)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Becton Dickinson is the larger company by revenue ($21.8B vs $4.7B) and market value ($41.9B vs $28.9B). Dexcom has grown revenue faster over the last 4 fiscal years (+90.4% cumulative vs +14.2%). Dexcom runs the higher operating margin (19.6% vs 11.8%). Becton Dickinson trades at the lower trailing P/E (26.5x vs 32.2x).
About Becton Dickinson
Becton Dickinson & Co (BD) is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. Its products serve healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. BD operates through three main segments: BD Medical, which offers medical technologies and devices; BD Life Sciences, which provides diagnostic and research tools; and BD Interventional, which supplies vascular, urology, oncology, and surgical specialty products.
About Dexcom
Dexcom Inc is a medical device company that designs, develops, and sells continuous glucose monitoring systems for diabetes and metabolic health management. Its main products include the Dexcom G7 and G7 15 Day systems, which provide real-time glucose readings and alerts to patients, caregivers, and clinicians. The company serves people with diabetes, including those using insulin, as well as adults with prediabetes and Type 2 diabetes who do not use insulin.
Head to head (BDX FY2025 vs DXCM FY2025)
| Metric | BDXFY2025 | DXCMFY2025 |
|---|---|---|
| Revenue | $21.84B | $4.66B |
| Revenue growth (YoY) | 8.2% | 15.6% |
| Gross margin | 45.4% | 60.1% |
| Operating margin | 11.8% | 19.6% |
| Net margin | 7.7% | 17.9% |
| Net income | $1.68B | $836.3M |
| Diluted EPS | $5.82 | $2.09 |
| FCF margin | 12.2% | 23.1% |
| ROE | 6.6% | 30.5% |
| Debt / equity | 0.7× | — |
| Market cap | $41.87B | $28.93B |
| P/E (TTM) | 26.5× | 32.2× |
Fundamentals are from each company’s SEC filings (BDX FY2025, DXCM FY2025). P/E and market cap are derived from recent market prices and update daily.
Five-year trend (as reported)
| Revenue | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| BDX | $19.13B | $18.87B | $19.37B | $20.18B | $21.84B |
| DXCM | $2.45B | $2.91B | $3.62B | $4.03B | $4.66B |
Peer standing
Where each company ranks among the 88 medical device companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | BDX | DXCM |
|---|---|---|
| Gross margin | 45.4%22nd percentile of 77 | 60.1%43rd percentile of 77 |
| Operating margin | 11.8%76th percentile of 80 | 19.6%92nd percentile of 80 |
| Net margin | 7.7%73rd percentile of 81 | 17.9%90th percentile of 81 |
| FCF margin | 12.2%71st percentile of 74 | 23.1%93rd percentile of 74 |
| Revenue growth (YoY) | +8.2%35th percentile of 87 | +15.6%57th percentile of 87 |
| ROE | 6.6%67th percentile of 79 | 30.5%95th percentile of 79 |
| P/E (TTM) | 26.5×39th percentile of 32 | 32.2×52nd percentile of 32 |
| Short interest (days to cover) | 2.90d40th percentile of 88 | 3.60d51st percentile of 88 |
Short interest
| FINRA settlement data | BDX | DXCM |
|---|---|---|
| Shares sold short | 11.2M | 18.1M |
| Change vs prior settlement | +54.4% | +6.4% |
| Days to cover | 2.90 | 3.60 |
| As of settlement | 2026-06-30 | 2026-06-30 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 open-market activity | BDX | DXCM |
|---|---|---|
| Buys | 0 | 0 |
| Sells | 6 ($765,120) | 10 ($5.3M) |
Open-market purchases and sales reported on SEC Form 4 (grants, exercises and tax withholding excluded). For context, about 16% of covered companies saw any open-market insider buy in a 90-day window.
Held by the same investors
7 tracked 13F managers hold both Becton Dickinson and Dexcom as of their latest quarterly filings: AQR Capital Management, Bridgewater Associates, Citadel Advisors, First Eagle Investment Management, Gotham Asset Management, Millennium Management, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
BDX vs BSXBDX vs MDLNBDX vs MMMBDX vs RMDBDX vs SYKBDX vs WSTAll medical device stocks →All comparisons →
Track BDX and DXCM
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.